![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Alembic’s Generic of Allergan’s Rapaflo Approved for Hyperplasia
Alembic’s Generic of Allergan’s Rapaflo Approved for Hyperplasia
![Purple_Approved_Stamp.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/Purple_Approved_Stamp.gif?t=1576639773&width=430)
Alembic Pharmaceuticals received the FDA’s approval for its Silodosin capsules (4mg and 8mg) as a generic to Allergan’s Rapaflo (silodosin).
Silodosin is a selective alpha 1 adrenergic receptor antagonist indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia.
The company now has a total of 108 ANDA approvals, including 96 final approvals and 12 tentative approvals.
Upcoming Events
-
21Oct